Paediatric and adolescent infections
Lead Research Organisation:
UNIVERSITY COLLEGE LONDON
Department Name: UNLISTED
Abstract
Infections are a very important reason why children get sick. In many parts of the world, large numbers of children still die from infectious diseases, like HIV, tuberculosis, malaria and blood infections. This programme of research uses different kinds of studies to answer questions about how we can best manage and treat infections in children and young people, both to reduce their chance of dying and being sick for longer, but also to increase their quality of life. This includes studies to work out what are the best drugs to use, thinking not just about controlling infections like HIV or curing infections like tuberculosis, but also what side-effects the drugs might have or how easy or hard families find it to take different numbers and types of pills every day. Other studies are working out what aspects of living with a long-term infection like HIV have the biggest impact on children and young people’s lives, including how they manage school and friends. The goal is to provide evidence so that national and international guidelines for managing children and young people with infections recommend the best options for them.
Technical Summary
This integrated programme of complementary randomised trials, cohorts and pharmacovigilance studies aims to address questions about medicines and other interventions relevant to the most frequent and serious infectious diseases affecting children worldwide, in particular HIV, tuberculosis, malaria and sepsis. This is important because infectious diseases still dominate as causes of childhood mortality and morbidity and disproportionately affect children in sub-Saharan Africa. The programme has a large international component in Europe, North and South America, Thailand and Africa, and is at the forefront of both national and international research in paediatric infectious diseases.
The most appropriate research study designs are used for each specific question, not repeating all studies done in adults but using research in adults to identify where questions may be different or likely have different answers in children. Recognising the relative paucity of research in children, multiple complementary questions are addressed in factorial trials wherever possible to increase the evidence base for clinical management, and add value to the original investment in setting up and running the trial. Substudies investigating aspects such as pharmacokinetics, immunology, virology, and adherence are also included alongside trials wherever possible, as are additional analyses of trial data in an observational framework. High quality additional long-term data can also be collected in trial extensions by linking to cohorts. However, not all questions regarding the optimal management and treatment of HIV-infected children can be answered by randomised trials, because many cannot be framed as an implementable intervention. Data from cohort studies are used to answer these population-level questions of major relevance to children, adolescents and their families.
Our future plans are
• to continue to address clinically relevant questions in paediatric infectious diseases through appropriate research designs, and
• to ensure that results are incorporated into national and international management guidelines and policy, and then into clinical practice, including through additional operational research if relevant.
Several randomised trials in HIV and tuberculosis are funded and in advanced planning phases. Ongoing analyses within cohorts and cohort collaborations led by the group are addressing a wide range of contextual topics that can be generalised to the treatment and care of the wider population of HIV-infected children and young people. A large programme of pharmacovigilance studies continues to provide important long-term safety data to the European Medicines Agency on newly licensed antiretroviral drugs for children.
The most appropriate research study designs are used for each specific question, not repeating all studies done in adults but using research in adults to identify where questions may be different or likely have different answers in children. Recognising the relative paucity of research in children, multiple complementary questions are addressed in factorial trials wherever possible to increase the evidence base for clinical management, and add value to the original investment in setting up and running the trial. Substudies investigating aspects such as pharmacokinetics, immunology, virology, and adherence are also included alongside trials wherever possible, as are additional analyses of trial data in an observational framework. High quality additional long-term data can also be collected in trial extensions by linking to cohorts. However, not all questions regarding the optimal management and treatment of HIV-infected children can be answered by randomised trials, because many cannot be framed as an implementable intervention. Data from cohort studies are used to answer these population-level questions of major relevance to children, adolescents and their families.
Our future plans are
• to continue to address clinically relevant questions in paediatric infectious diseases through appropriate research designs, and
• to ensure that results are incorporated into national and international management guidelines and policy, and then into clinical practice, including through additional operational research if relevant.
Several randomised trials in HIV and tuberculosis are funded and in advanced planning phases. Ongoing analyses within cohorts and cohort collaborations led by the group are addressing a wide range of contextual topics that can be generalised to the treatment and care of the wider population of HIV-infected children and young people. A large programme of pharmacovigilance studies continues to provide important long-term safety data to the European Medicines Agency on newly licensed antiretroviral drugs for children.
Organisations
- UNIVERSITY COLLEGE LONDON (Lead Research Organisation)
- Wellcome Trust (Collaboration)
- The Sainsbury Family Charitable Trusts (Collaboration)
- ST GEORGE'S UNIVERSITY OF LONDON (Collaboration)
- University of Padova (Collaboration)
- Kenyan Institute for Medical Research (KEMRI) (Collaboration)
- MOI UNIVERSITY (Collaboration)
- University Teaching Hospital (Collaboration)
- Institute of Post Graduate Medical Education And Research (Collaboration)
- Kalawati Saran Children's Hospital (Collaboration)
- International AIDS Society (IAS) (Collaboration)
- Makerere University (Collaboration)
- University College London (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Gilead Sciences, Inc. (Collaboration)
- University of Cape Town (Collaboration)
- University of Zimbabwe (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Radboud University Nijmegen Medical Center (Collaboration)
- Johnson & Johnson (Collaboration)
- London School of Hygiene and Tropical Medicine (LSHTM) (Collaboration)
- Hanoi Lung Hospital (Collaboration)
- University of Antwerp (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- Pham Ngoc Thach Hospital (Collaboration)
- Joint Clinical Research Center, Kampala (Collaboration)
- European Commission (Collaboration)
Publications
Abongomera G
(2015)
Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.
in BMC health services research
Abongomera G
(2017)
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
in AIDS and behavior
Ades AE
(2023)
Overall Vertical Transmission of Hepatitis C Virus, Transmission Net of Clearance, and Timing of Transmission.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Ades AE
(2023)
Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Andrew J. Prendergast
(2019)
Seeking interventions to reduce post-discharge mortality among children in sub-Saharan Africa
Andrew J. Prendergast
(2019)
Seeking interventions to reduce post-discharge mortality among children in sub-Saharan Africa
| Description | Ali Judd: Scientific Committee Member of the International Workshop on HIV Pediatrics. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Guideline Title | Guidelines for the use of antiretroviral agents in pediatric HIV infection |
| Description | Citation in NIH paediatric HIV guidelines, 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0 |
| Description | EMA approves use of dolutegravir 5mg dispersible tablet for younger children living with HIV, based, in part, on data from ODYSSEY |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| Impact | This licensing decision means that young children living with HIV can access dolutegravir, which helps to expand the use of dolutegravir in children and close the gap between HIV treatment options available for adults and children. |
| URL | https://www.ctu.mrc.ac.uk/news/news-stories/2020/november/european-medicines-agency-approves-use-of-... |
| Description | FDA approves use of adult dolutegravir tablets for children over 20kg in weight, and 5mg dispersible tablets for children >3kg, based in part on ODYSSEY data |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| Impact | The approval of adult 50mg DTG for use for children weighing =20kg allows for immediate access to adult DTG formulation, which is available in many countries for the majority of children living with HIV. Dispersible DTG formulations will provide an age-appropriate option for a younger population making it easy for children who are unable to swallow tablets to take this medication. This successful submission is a major step in closing the gap between the HIV treatment options available for adults and children. These decisions were based in part upon data from the ODYSSEY trial. |
| URL | https://viivhealthcare.com/en-gb/media/press-releases/2020/june/viiv-healthcare-announces-us-fda-app... |
| Guideline Title | WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children |
| Description | Influence on WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | The new WHO guidelines recommend that rapid fluid resuscitation is not used for children with 1 or 2 signs of shock, following the results of the FEAST trial. However, they still recommend (more conservative) fluid resuscitation for children with all three signs of shock. FEAST found that rapid fluid resuscitation was associated with excess mortality for children with any definition of shock. The new guidelines are progress, but do not completely accord with the FEAST recommendations. |
| URL | http://apps.who.int/iris/bitstream/10665/204463/1/9789241510219_eng.pdf?ua=1 |
| Description | Lablite training handbook adopted by Ugandan Ministry of Health |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Member of CIPHER Steering Committee |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Member, Paediatric/ Obstetric Subgroup of the HIV Clinical Reference Group, NHS |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Membership of WHO Guidelines Development Group (GDG) for Treating and Preventing HIV Infection |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Impact | The updated WHO recommendations to inform the consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection - recommendations for a public health approach issued in 2021. The guidelines contributed to the new Global Programme of Work - Triple-Billion initiative - as part of the Global Public Health Goods 1.1.2. |
| URL | https://cdn.who.int/media/docs/default-source/hiv-hq/proposed_membership_2020servicedeliverygdg-v2e1... |
| Description | Membership of WHO Guidelines Development Group (GDG) on recommendations on preferred first-line and second-line antiretroviral regimens for treating HIV infection |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Update of recommendations on first- and second-line antiretroviral regimens: policy brief. July 2019 (WHO guidelines) were released in 2019. The guidance recommended earlier diagnosis and treatment of HIV, associated with improved health outcomes. |
| URL | https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/ |
| Description | Memebership of WHO Guidelines Development Group: Update of recommendations for treatment and prevention of HIV infection October 2020. Anna Turkova |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Guideline Title | Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: Interim guidance. Annex 3 |
| Description | ODYSSEY Pharmacokinetics data influences WHO paediatric dosing guidelines |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.who.int/hiv/pub/guidelines/ARV_Guidelines-2018-Annex3.pdf?ua=1 |
| Description | Penta English and Russian courses in Paediatric HIV, hepatitis and congenital infections - online modules and tutorial support |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Penta training courses reach wide audiences of healthcare workers in Western and Eastern Europe and Central Asia providing medical care to children and adolescents living with HIV. |
| Guideline Title | Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children |
| Description | Surviving sepsis guidelines |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Leaders in the paediatric field have now indicated maintenance fluid only in resource limited setting, where ICU care is not possible |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/32032264 |
| Guideline Title | Emergency Triage and Treatment of Children (RCPCH) |
| Description | TRACT results influence ETAT recommendations for volume of blood to transfuse for children with severe anaemia |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | ETAT guidelines have been updated to recommend giving whole blood at 20ml/kg over 3 hours if the child's temperature is over 37.5 degrees C, or 30mls/kg if the temperature is 37.5 degrees C or below. This is based on the results of the TRACT trial. |
| Description | WHO: Programmatic Management of Latent TB Infection |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | A randomized controlled trial of shorter course treatment for uncomplicated minimal childhood tuberculosis (SHINE) |
| Amount | £3,217,996 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 10/2018 |
| Description | Adolescents and Adults Living with Perinatal HIV cohort (AALPHI)/ Monument Trust (Sainsbury Family) |
| Amount | £850,000 (GBP) |
| Organisation | The Sainsbury Family Charitable Trusts |
| Department | Monument Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2011 |
| End | 12/2015 |
| Description | Benefit-Kids - TB CHAMP extension |
| Amount | $3,726,050 (USD) |
| Organisation | World Health Organization (WHO) |
| Department | UNITAID |
| Sector | Public |
| Country | Switzerland |
| Start | 09/2019 |
| End | 10/2022 |
| Description | CIPHER Cohort Collaborative Projects ($ 142964; 2014 - 2015) |
| Amount | $46,842 (USD) |
| Organisation | International AIDS Society (IAS) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 01/2016 |
| End | 12/2018 |
| Description | CIPHER Data Platform |
| Amount | $275,220 (USD) |
| Organisation | International AIDS Society (IAS) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 01/2020 |
| End | 12/2021 |
| Description | Collaborative Award (Severe Malaria Africa - A consortium for Research and Trials (SMAART)) |
| Amount | £3,944,185 (GBP) |
| Funding ID | 209265 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 06/2023 |
| Description | Collaborative HIV Paediatric Study (CHIPS) |
| Amount | £870,000 (GBP) |
| Organisation | NHS England |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2010 |
| End | 03/2020 |
| Description | HCVAVERT: designing a trial to cure hepatitis C virus (HCV) in HCV-infected pregnant women And prevent VERTical HCV transmission |
| Amount | £148,437 (GBP) |
| Funding ID | MR/R019746/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 12/2021 |
| Description | Health Protection Research Unit, Blood Borne and Sexually Transmitted Infections |
| Amount | £3,711,258 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2014 |
| Description | IAS CIPHER |
| Amount | £294,366 (GBP) |
| Organisation | International AIDS Society (IAS) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 05/2018 |
| End | 12/2019 |
| Description | Joint Global Health Trial Development Grant (TABS) |
| Amount | £158,075 (GBP) |
| Funding ID | MR/P021492/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2019 |
| Description | Joint Global Health Trials (H-PRIME trial) |
| Amount | £4,375,063 (GBP) |
| Funding ID | MR/P74363/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 06/2025 |
| Description | MRC Training Fellowship - Felicity Fitzgerald |
| Amount | £205,907 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2013 |
| End | 09/2016 |
| Description | NHS England - CHIPS |
| Amount | £150,000 (GBP) |
| Organisation | NHS England |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2019 |
| Description | ODYSSEY qualitative substudy - how does moving to second line HIV treatment affect young people's treatment engagement - additional funding |
| Amount | £47,678 (GBP) |
| Organisation | Viiv Healthcare |
| Sector | Private |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 09/2020 |
| Description | ODYSSEY substudy: Folate and vitamin B12 status among children and adolescents in the ODYSSEY trial |
| Amount | £32,476 (GBP) |
| Organisation | Viiv Healthcare |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 05/2020 |
| Description | PENTA Foundation, EPPICC grant |
| Amount | £1,618,051 (GBP) |
| Organisation | PENTA Foundation |
| Sector | Academic/University |
| Country | France |
| Start | 01/2016 |
| End | 12/2020 |
| Description | Reduction of Early mortaLITY in HIV-infected African adults and children starting antiretroviral therapy: REALITY trial |
| Amount | £3,986,746 (GBP) |
| Funding ID | MC_EX_G1100693 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2012 |
| End | 03/2018 |
| Description | SURE+DP: Improving Diagnosis and Prognosis for paediatric tuberculous meningitis through the SURE treatment trial |
| Amount | £249,917 (GBP) |
| Organisation | Meningitis Now |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 07/2023 |
| Description | Severe Malaria Africa - A consortium for Research and Trials (SMAART) |
| Amount | £4,028,013 (GBP) |
| Funding ID | 209265/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 06/2025 |
| Description | TB CHAMP: Tuberculosis Child Multidrug-resistant Preventive Therapy Trial |
| Amount | £463,638 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2019 |
| Description | UNIVERSAL: Pharmacokinetic and safety studies of new antiretroviral formulations: expediting UNIVERSAL first and second line regimens for all children living with HIV in Africa |
| Amount | € 3,999,818 (EUR) |
| Organisation | Sixth Framework Programme (FP6) |
| Department | European and Developing Countries Clinical Trials Partnership |
| Sector | Public |
| Country | Netherlands |
| Start | 01/2021 |
| End | 01/2026 |
| Description | ViiV PENTA (20) ODYSSEY additional funding |
| Amount | £1,549,242 (GBP) |
| Organisation | Viiv Healthcare |
| Sector | Private |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 06/2022 |
| Description | ViiV: investigator sponsored study |
| Amount | £6,614,624 (GBP) |
| Organisation | Viiv Healthcare |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 05/2021 |
| Description | Wellcome Trust Collaborative Award in Science |
| Amount | £3,944,185 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 06/2024 |
| Description | Wellcome Trust Fellowship Helen Payne (Immunology substudies in CHER Trial) |
| Amount | £314,606 (GBP) |
| Funding ID | 095182/Z/10/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2011 |
| End | 07/2015 |
| Description | Wellcome Trust Fellowship Julia Kenny (CHAPAS 3 Trial & Substudies) |
| Amount | £371,694 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2012 |
| End | 07/2016 |
| Title | AALPHI database |
| Description | The AALPHI database contains clinical, neurocognitive and psychsocial data on 300 vertically HIV-infected young people and a comparison group of 100 HIV negative controls in the UK. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | Recruitment is in progress. This work is expected to significantly contribute to the evidence base on how to treat young people with vertical HIV in the future. |
| Title | CHIPS database |
| Description | Establishment of collaborative database containing clinical data on HIV-infected children in the UK/Ireland |
| Type Of Material | Database/Collection of data |
| Provided To Others? | Yes |
| Impact | Many publications written by us, and by collaborators, over the years - see URL below. Citations in international clinical guidelines. |
| URL | http://www.chipscohort.ac.uk/default.asp |
| Title | CIPHER database |
| Description | Establishment of collaborative database containing clinical data on HIV-infected children in globally, representing all regions |
| Type Of Material | Database/Collection of data |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | Under development |
| Title | EPPICC database |
| Description | Establishment of collaborative database containing clinical data on HIV-infected children in Europe |
| Type Of Material | Database/Collection of data |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | Development of database has resulted in collaborative research projects and publications, both within the EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration) group, and in collaboration with other cohort collaborations, such as COHERE and EuroCoord. |
| URL | http://penta-id.org/hiv/eppicc-studies.html |
| Description | CAPIT: University of Antwerp |
| Organisation | University of Antwerp |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | There has been very considerable advances in molecular microbiology since the CAP-IT grant was first submitted. Whole Genome Sequencing of the pneumococcus and other relevant bacteria has led a recognition of the complexity of genotypic assessment of penicillin resistance adding significantly to our understanding of this very complex area. Our proposal is to collaborate further with Antwerp and their molecular microbiology facility to undertake WGS and metagenomics on the nasopharyngeal specimens to obtain the maximal scientific utility from these very important specimens. |
| Collaborator Contribution | Still ongoing |
| Impact | No outputs yet |
| Start Year | 2019 |
| Description | CAPIT: University of Antwerp |
| Organisation | University of Antwerp |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | There has been very considerable advances in molecular microbiology since the CAP-IT grant was first submitted. Whole Genome Sequencing of the pneumococcus and other relevant bacteria has led a recognition of the complexity of genotypic assessment of penicillin resistance adding significantly to our understanding of this very complex area. Our proposal is to collaborate further with an internationally recognised molecular microbiology facility to undertake WGS and metagenomics on the nasopharyngeal specimens to obtain the maximal scientific utility from these very important specimens. |
| Collaborator Contribution | There has been very considerable advances in molecular microbiology since the CAP-IT grant was first submitted. Whole Genome Sequencing of the pneumococcus and other relevant bacteria has led a recognition of the complexity of genotypic assessment of penicillin resistance adding significantly to our understanding of this very complex area. Our proposal is to collaborate further with an internationally recognised molecular microbiology facility to undertake WGS and metagenomics on the nasopharyngeal specimens to obtain the maximal scientific utility from these very important specimens. |
| Impact | No output yet. |
| Start Year | 2019 |
| Description | EPPICC (European Paediatric and Pregnancy HIV Cohort Collaboration) |
| Organisation | University of Padova |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | We co-lead this network of paediatric observational HIV cohorts along with the Institute for Child Health. We have co-written the strategic plan for this network for the next 5 year period and have contributed to the EuroCoord bid which has secured funding for this network for the next 5 years. |
| Collaborator Contribution | We are leading a new collaborative project (EPPICC infants) for this network, and the network has provided us with data to make the project feasible. The network also contributes epidemiological and clinical expertise to the project. |
| Impact | Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009,23:597-604. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Fosamprenavir use in children in the European Union. A report to the European Medicines Agency (EMA), August 2009 (and repeated August 2010). London: MRC Clinical Trials Unit. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS. 2011;25:2279-2287. |
| Start Year | 2007 |
| Description | Eldoret, Kenya |
| Organisation | Moi University |
| Country | Kenya |
| Sector | Academic/University |
| PI Contribution | MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis. |
| Collaborator Contribution | The Eldoret site are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients. |
| Impact | Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. Multiple clinical trial grants, including EARNEST and REALITY trials. Publications reporting the results of these trials which have influenced national, regional and international guidelines. |
| Start Year | 2010 |
| Description | EuroCoord |
| Organisation | European Commission |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | scientific lead in writing project proposal; major partner. running paediatric PENTA trials and coordinating EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration). |
| Collaborator Contribution | scientific coordinator 2011-2012 (Work Package 3). data harmonisation |
| Impact | The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infectious Diseases. April: 2011, 273-283. |
| Start Year | 2011 |
| Description | Gilead |
| Organisation | Gilead Sciences, Inc. |
| Department | Gilead |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Design and conduct of trial protocol |
| Collaborator Contribution | Review of protocol; provision of free drug |
| Impact | Final protocol; fpfv planned Q2 2016; clinical, virology, immunology, pharmacokinetics |
| Start Year | 2015 |
| Description | Gilead Sciences |
| Organisation | Gilead Sciences, Inc. |
| Department | Gilead |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team ran the trial: Gilead contributed drugs and funding for specific substudies. |
| Collaborator Contribution | Provided drugs for the trial |
| Impact | Gilead provided first-line drugs for the trial, without which there would have been no publications. They also provided specific funding for PMID 18444867, 18839777 and for the current PENTA 17 (SMILE) elvitegravir trial |
| Description | Harvard University |
| Organisation | Harvard University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration. |
| Collaborator Contribution | Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration. |
| Impact | Outputs are being generated and are forthcoming. |
| Start Year | 2014 |
| Description | IAS |
| Organisation | International AIDS Society (IAS) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration, hosted at IAS. Also collaboration between UCL and IAS for a global paediatric HIV pharmacovigilance study. |
| Collaborator Contribution | Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration, hosted at IAS. Also collaboration between UCL and IAS for a global paediatric HIV pharmacovigilance study. |
| Impact | Outputs forthcoming |
| Start Year | 2014 |
| Description | INSERMSC10- US019.Essais thérapeutiques et maladies infectieuses |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Department | INSERM SC10 - US019 |
| Country | France |
| Sector | Public |
| PI Contribution | Collaboration on management and co-ordination of PENTA trials |
| Collaborator Contribution | Collaboration on management and co-ordination of PENTA trials |
| Impact | All PENTA trials |
| Description | Institute of Child Health |
| Organisation | University College London |
| Department | Institute of Child Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaborators on an MRC Immunology substudy within ARROW, delegating activities as described under an agreement with ICH, and we take responsibility for the project in accordance with the provisions of the Funder; application for NIHR funding for PENTA 16 immunology substudy |
| Collaborator Contribution | Training, laboratory capacity building, teaching on PENTA Courses in East and West Europe and across Africa; sharing supervision of PhD Wellcome Trust studentships (Prof. Nigel Klein). Working together on EuroCoord, EPPICC, PENTA and Hepatitis C activities (Dr Claire Thorne). Collaborators and grant holders on NIHR PENTA 16 main study and biomarker substudy |
| Impact | MRC grant secured in 2010. Work ongoing with baseline data presented at international conferences. Involves collaboration, training and capacity building between clinical, laboratory and trial management personnel at Ugandan and Zimbabwean sites and MRC CTU and Institute of Child Health. Site laboratory trained in four colour Immunophenotyping, nucleic acid extraction protocols and quantitative and real time PCRs (on HIV, CMV and EBV), and ELISA assays. Further training will be done on other techniques, in year 2 of the study. Training was done by personnel from both CTU and ICH. |
| Start Year | 2010 |
| Description | JCRC, Uganda |
| Organisation | Joint Clinical Research Center, Kampala |
| Country | Uganda |
| Sector | Academic/University |
| PI Contribution | MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis. |
| Collaborator Contribution | JCRC are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site in multiple trials over the last decade. |
| Impact | Multidiscplinary, including clinical medicine, statistics, trial management, laboratory management. Multiple clinical trial grants, including DART, ARROW, CHAPAS-3, EARNEST and REALITY trials. Multiple publications reporting the results of these trials which have influenced national, regional and international guidelines. |
| Description | Janssen Pharmaceutica |
| Organisation | Johnson & Johnson |
| Department | Janssen Pharmaceutica |
| Country | Global |
| Sector | Private |
| PI Contribution | We coordinate the EPPICC pharmacovigilance project which provides long-term safety of paediatric HIV drugs to Janssen/ European Medicines Agency. |
| Collaborator Contribution | We coordinate the EPPICC pharmacovigilance project which provides long-term safety of paediatric HIV drugs to Janssen/ European Medicines Agency. |
| Impact | European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand. Antiviral Therapy, in press |
| Start Year | 2011 |
| Description | KEMRI, Kilifi |
| Organisation | Kenyan Institute for Medical Research (KEMRI) |
| Country | Kenya |
| Sector | Public |
| PI Contribution | MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis |
| Collaborator Contribution | KEMRI are collaborating on the REALITY trial in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients. |
| Impact | Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. REALITY clinical trial grant. |
| Start Year | 2012 |
| Description | Kalawati Saran Children's Hospital (Lady Hardinge Hospital - LHH), Delhi |
| Organisation | Kalawati Saran Children's Hospital |
| Country | India |
| Sector | Public |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Description | MLW, Malawi |
| Organisation | Wellcome Trust |
| Department | Malawi-Liverpool Wellcome Trust Clinical Research Programme |
| Country | Malawi |
| Sector | Academic/University |
| PI Contribution | MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis |
| Collaborator Contribution | MLW are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site. |
| Impact | Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. Multiple clinical trial grants, including EARNEST and REALITY trials. Publications reporting the results of these trials which have influenced national, regional and international guidelines. |
| Start Year | 2010 |
| Description | Makerere University - Johns Hopkins University (MU-JHU), Kampala |
| Organisation | Makerere University |
| Country | Uganda |
| Sector | Academic/University |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Description | Monument Trust |
| Organisation | The Sainsbury Family Charitable Trusts |
| Department | Monument Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | MRC CTU co-ordinates the CHAPAS-2 trial and the AALPHI study |
| Collaborator Contribution | funding. The Monument Trust also contribute to I-Base publications which CTU staff have input in to. |
| Impact | The Monument Trust funds the pharmacokinetic teams at 2 of the Ugandan trial centres for ARROW and CHAPAS trials. Some second-line children from ARROW are co-enroled in CHAPAS-2. AALPHI study started recruiting in Q3 2012. |
| Start Year | 2010 |
| Description | National Institute of Health |
| Organisation | National Institutes of Health (NIH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Provide scientific input in to all aspects of desgin, analysis and write up of the CHER trial (Prof Diana Gibb and Prof Abdul Babiker). With Prof Lynne Mofenson at NIAID we have worked on PENPACT-1 trial and cohort collaborations (HPPMCS). |
| Collaborator Contribution | We have collaborated with NIH who funded the CHER trial in South Africa through a CIPRA grant. NIH have contributed funding and collaboration on the PENPACT-1 trial |
| Impact | Papers from the CHER trial and PENPACT-1 trial, papers from HPPMCS. |
| Description | National Lung Hospital, Hanoi |
| Organisation | Hanoi Lung Hospital |
| Country | Viet Nam |
| Sector | Hospitals |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Description | OXFORD UNIVERSITY CLINICAL TRIALS UNIT (OUCRU) Vietnam |
| Organisation | University of Oxford |
| Department | Oxford University Clinical Research Unit Vietnam (OUCRU) |
| Country | Viet Nam |
| Sector | Academic/University |
| PI Contribution | Co-coordinating trial unit for the SURE study |
| Collaborator Contribution | Co-coordinating trial unit for the SURE study |
| Impact | Co-coordinating trial unit for the SURE study |
| Start Year | 2019 |
| Description | Ph?m Ng?c Th?ch hospital, Ho Chi Minh City |
| Organisation | Pham Ngoc Thach Hospital |
| Country | Viet Nam |
| Sector | Hospitals |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Description | Post Graduate Institute of Education and Medical Research (PGI), Chandigarh |
| Organisation | Institute of Post Graduate Medical Education And Research |
| Country | India |
| Sector | Academic/University |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Description | Radboud University Nijmegen Medical Centre, the Netherlands |
| Organisation | Radboud University Nijmegen Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | The research team at the MRC co-ordinates the ARROW, CHAPAS-1,2,3 and PENTA trials and provides scientific input and analysis of EDCTP funded VITA 1 and 2 trials. |
| Collaborator Contribution | Long standing nesting of key pharmacokinetic studies within larger trial programmes. Contributed to several PhD studentships (all Dutch), PK data resulted in licensing of new appropriate antiretroviral formulations for children in resource limited settings. |
| Impact | Radbound University has been involved in the analysis and writing up of the pharmacokinetics data from ARROW, PENTA 18 and the CHAPAS trials which has resulted in presentations at international conferences, peer review publications, FDA and EMA approval of drugs and Clinton Foundation and UNITAID dissemination in Africa. |
| Start Year | 2007 |
| Description | SGUL |
| Organisation | St George's University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | design and conduct of study protocol. |
| Collaborator Contribution | SGUL - Chief Investigator and Trial Physician; PERUKI, Universities of Oxford/Bristol /UCL ICH- design and analysis of laboratory studies; University of Southampton Health Economics |
| Impact | Multi-disciplinary - clinical, health economics, laboratory |
| Start Year | 2013 |
| Description | The London School of Hygiene and Tropical Medicine |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Faculty of Public Health and Policy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | coordination and facilitation of the Young Lives substudy in the ARROW trial, qualatative substudy of PENTA 16 (UK, Uganda and US) and input in to AALPHI. |
| Collaborator Contribution | intensive training in areas of social science adding to collaborations in the African centres (ARROW and PENTA 16). provision of a forum for young people in the ARROW trial to contribute to knowledge about living with HIV infection in Africa |
| Impact | 3 Social Scientists trained in Africa; publications and presentations at major conferences on qualitative work in ARROW and BREATHER (PENTA 11) |
| Start Year | 2011 |
| Description | UZCRC, Zimbabwe |
| Organisation | University of Zimbabwe |
| Department | University of Zimbabwe Clinical Research Centre |
| Country | Zimbabwe |
| Sector | Academic/University |
| PI Contribution | MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis |
| Collaborator Contribution | UZCRC are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site in multiple trials over the last decade. |
| Impact | Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management. Multiple clinical trial grants, including DART, ARROW, EARNEST and REALITY trials. Multiple publications reporting the results of these trials which have influenced national, regional and international guidelines. |
| Description | University Teaching Hospital (UTH), Lusaka |
| Organisation | University Teaching Hospital |
| Country | Zambia |
| Sector | Hospitals |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Description | University of Cape Town |
| Organisation | University of Cape Town |
| Department | Division of Clinical Pharmacology |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | MRC CTU coordinates the CHAPAS 3, PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials. |
| Collaborator Contribution | Dr Helen McIlleron's team designed, coordinate and analyse pharmacokinetic studies in collaboration with Prof David Burger from Nimejgen. Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration. Clinical site for PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials |
| Impact | Analyses of CHAPAS 3 data are currently in progress |
| Start Year | 2010 |
| Description | University of Zimbabwe Clinical Research Centre (UZCRC), Harare |
| Organisation | University of Zimbabwe |
| Department | University of Zimbabwe Clinical Research Centre |
| Country | Zimbabwe |
| Sector | Academic/University |
| PI Contribution | This is a recruiting site to the SURE study |
| Collaborator Contribution | This is a recruiting site to the SURE study |
| Impact | This is a recruiting site to the SURE study |
| Start Year | 2019 |
| Title | CAP-IT - amoxicillin |
| Description | Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community Acquired Pneumonia (CAP): a randomIsed controlled Trial (CAP-IT). Funded by NIHR HTA. Recruitment started Q1 2017. Collaboration with PERUKI, SGUL, Universities of Bristol, Southampton, Oxford. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2016 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Feasibility study completed. Pilot study will include validation of saliva swabs against nasopharyngeal swabs for identification of S.pneumoniae and identification of changes in antibiotic resistance. |
| URL | http://www.isrctn.com/ISRCTN76888927 |
| Title | Enhanced opportunistic infection prophylaxis |
| Description | In the REALITY trial we tested a "bundle" of drugs as enhanced prophylaxis for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (>5 years) with severe immunosuppression when they start anti-HIV treatment, to see if the bundle reduces early mortality on treatment. The bundle contains isoniazid (anti-tuberculosis), fluconazole (anti-cryptococcus), azithromycin (anti-bacterial infections) and albendazole (anti-helminths). This reduced mortality after starting treatment by 25%, and has been included in WHO guidelines. It has recently been shown to be the most cost-effective of 6 different prophylaxis strategies for late presenting HIV patients. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2016 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | None |
| URL | http://www.isrctn.com/ISRCTN43622374 |
| Title | ODYSSEY - PENTA 20 |
| Description | ODYSSEY (Once daily dolutegravir in young people vs standard therapy) - A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART. FPFV due April 2016. Funding from EU, PENTA Foundation, ViiV, INSERM. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Market authorisation |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | n/a |
| URL | http://penta-id.org |
| Title | Plumpynut |
| Description | Plumpynut is a nutritional supplement made from peanuts, and including specific multi-vitamins and multi-minerals. In the REALITY trial we tested using it as adjunctive therapy for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (>5 years) with severe immunosuppression when they start anti-HIV treatment, to see if it reduced early mortality on treatment. It did lead to greater weight gain, but did not impact mortality. It therefore should not be recommended at present as a way to reduce mortality in late HIV presenters. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2016 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | None. |
| URL | http://www.isrctn.com/ISRCTN43622374 |
| Title | Raltegravir |
| Description | Raltegravir is an integrase inhibitor licenced for the treatment of HIV infection. In the REALITY trial we tested using it as adjunctive therapy for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (>5 years) with severe immunosuppression when they start anti-HIV treatment, to see if it reduced early mortality on treatment. Raltegravir did reduce HIV viral load much faster when combined with standard of care, but this did not lead to any improvements in mortality. Adjunctive raltegravir could be useful in women identified as infected during pregnancy (as it reduces viral load faster, hence reducing transmission risk to the unborn child) but does not have wider utility in HIV late presenters. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2016 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | None. |
| URL | http://www.isrctn.com/ISRCTN43622374 |
| Title | elvitegravir |
| Description | A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | First patient expected Q2 2016 |
| URL | http://www.penta-id.org |
| Description | Animation for children about Pharmacokinetics study for CHAPAS4 |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | We produced two versions of an animation (one for younger children and one for older children) explaining what a pharmacokinetic study is, and how it helps work out what dose of medicines children need. https://vimeo.com/360240727 and https://vimeo.com/360240749 |
| Year(s) Of Engagement Activity | 2019,2020 |
| URL | https://vimeo.com/360240727 |
| Description | Anna Turkova: PADO-4: Paediatric ARV Drug Optimization 4 Meeting Invited talk: Treatment simplification strategies |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | World Health Organisation meeting, PADO-4 (Paediatric ARV Drug Optimization 4) meeting where Anna Turkova was invited to present 'Treatment simplification strategies.' WHO recently convened Paediatric Antiretroviral Drug Optimization (PADO) Meeting 4 to take stock of the progress made and further advance the agenda for optimizing antiretroviral therapy for children. This meeting aimed to review the medium- and long-term priorities for drug and formulation development and to identify additional research gaps in this area. The meeting brought together researchers, clinicians, programme managers and other stakeholders and provided the opportunity to foster coordination and further develop collaborations to take the required actions for scaling up treatment for children and adolescents living with HIV. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Anna Turkova: The International Liver Congress |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The International Liver Congress is the annual EASL meeting, and Anna Turkova was invited to speak at the EASL-WHO symposium, 'Promoting access to DAAs for children and adolescents and experience of use in pregnant women).' Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research. The annual Congress attracts around 10,000 delegates and 250 media representatives from all over the world making this a truly international networking opportunity! |
| Year(s) Of Engagement Activity | 2019 |
| Description | Annual meeting of the Child and Adolescent TB working group: Update on SHINE trial |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Update on SHINE trial - a phase III randomised trial of treatment shortening in children with minimal TB disease presented at the annual WHO Child and Adolescent TB working group. |
| Year(s) Of Engagement Activity | 2019 |
| Description | BREATHER (PENTA 16) results |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of the results of the trial at a major scientific conference. Butler K on behalf of the BREATHER trial team: ART with weekends off is non-inferior to continuous ART in young people on EFV+2 NRTI. CROI 2015, Seattle, USA, Feb 23 -26 2015. Oral presentation abstract 38LB. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://penta-id.org |
| Description | BREATHER briefing paper |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | We produced a briefing paper on the BREATHER trial results. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ctu.mrc.ac.uk/13706/13710/breather_briefing_paper |
| Description | Blog |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | I wrote a blog that has been published by the Centre for Maternal, Adolescent, Reproductive, & Child Health (MARCH) at the London School of Hygiene & Tropical Medicine exploring the growing population of children who are HIV-exposed but uninfected (https://www.lshtm.ac.uk/research/centres/march-centre/news/88751 or Short link: bit.ly/exposeduninfected). The blog has received over 140 visitors and has been publicised in the LSHTM and MARCH newsletters and sparked feedback, requests for further information and interest in the topic. |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://bit.ly/exposeduninfected |
| Description | CAPIT Meta-Analysis Poster Presentation - RCPCH |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meta-analysis poster displayed at the RCPCH 2019 conference summarising the findings from the meta-planning exercise results from the trial's investigator's meeting September 2018. |
| Year(s) Of Engagement Activity | 2019 |
| Description | CHAPAS-4 stakeholder mapping and communication training workshops |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We ran four workshops for CHAPAS-4 partners, which covered stakeholder mapping, developing communications strategies, writing key messages, writing for non-scientific audiences and presenting to non-scientific audiences. The workshops were held in Zambia, Zimbabwe, and two in Uganda. Attendees reported that the training was very helpful. Based on the stakeholder mapping we have now developed the communications strategy for CHAPAS-4. |
| Year(s) Of Engagement Activity | 2018,2019,2020 |
| Description | CHIVA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Twice yearly contribution of lay text on the CHIPS study to the CHIVA Newsletter; yearly presentation of key findings from the CHIPS and AALPHI studies at the CHIVA national conference. Updating on results and ongoing PENTA trials Improved reporting of patients to CHIPS, and general understanding of the CHIPS data and its importance. Recruitment of patients into PENTA trials |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016,2017 |
| Description | CHIVA Annual Conference: Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker to the annual CHIVA conference in London. Title of talk: PENTA - A global Update |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.chiva.org.uk/professionals/previous-conferences/2019-annual-chiva-conference/ |
| Description | CROI 2020 keynote talk Ali Judd |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote talk at Conference of Retroviruses and Other Infections (CROI) 2020 Ali Judd presented 'VERTICAL HEPATITIS C TRANSMISSION: DÉJÀ VU ALL OVER AGAIN?' As part of the Hepatitis C: Parallels, Pitfalls and Promise Symposium. |
| Year(s) Of Engagement Activity | 2020 |
| Description | CTU Seminar Series: Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | About 80 people attended the seminar which was highlighting the impact of the CHAPAS HIV trials that have been conducted from the CTU and led by Prof Gibb over the past 20 years. The seminar sparked questions around the future of the CHAPAS trials and the international collaborations. Title of talk: Impact of the CHAPAS trials |
| Year(s) Of Engagement Activity | 2019 |
| Description | ESPID Plenary Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | I as invited and gave the plenary lecture at ESPID (European Society for Paediatric Infectious Diseases) which is an international conference addressing clinicians and policymakers. The talk ws well recieved to an audience of over 100 and which discussed the trials run from CTU, SHINE/CHAMP/SURE/STREAM/REALITY/CAPIT/ODYSSEY/ARROW Title of the talk: New ways of doing clinical trials in infectious diseases to maximise evidence generation |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited speaker at PENTA HIV Training |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at the international HIV paediatric training programme run by PENTA ID. Title of talk; TB Research Update/Research and adolescents, trials and their involvement |
| Year(s) Of Engagement Activity | 2019 |
| Description | Lablite training briefing paper |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We produced a briefing paper summarising the training approach used within Lablite. This briefing paper was distributed at the International AIDS Conference in Durban. |
| Year(s) Of Engagement Activity | 2016 |
| Description | London Specialised Commissioning Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Annual production of a newsletter (annual report) and slide set which presents CHIPS data in lay language. Presentation of data at twice yearly London HIV Consortium meetings CHIPS data are now used as the basis for commissioning paediatric HIV services across England, and are being developed to measure quality of services within new designation schemes. |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016 |
| Description | MRC Festival Workshop on Getting Results Faster for Patients |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | As part of the Medical Research Council (MRC) Festival of Medical Research, the MRC Clinical Trials Unit at University College London (MRC CTU at UCL) held a half-day workshop exploring how the Unit is working to get faster results and impact from clinical trials. We invited patient representatives involved in our studies, and patient groups who are interested in clinical trials. 30 people from 20 patient groups and various trials attended the workshop, along with around 20 members of MRC CTU at UCL staff. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ctu.mrc.ac.uk/news/2016/getting_results_faster_workshop_report_010816 |
| Description | Media Publications |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Results reported from the REALITY trial in Paris for the IAS conference on HIV science where published by the British media. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.theguardian.com/global-development/2017/jul/24/cocktail-of-drugs-could-prevent-10000-hiv... |
| Description | Meeting of paediatricians and blood transfusion services from across sub-Saharan Africa |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The TRACT trial team, in partnership with the African Society for Blood Transfusion and Uganda Paediatric Society, convened a meeting bringing together leading paediatricians and blood transfusion services from across sub-Saharan Africa, to discuss the results of the trial and what they mean for policy and practice. A treatment algorithm was developed at the meeting. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Membership of the WHO Paediatric Antiretroviral Drug Optimisation (PADO) group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Providing expert opinion, related to development of new drugs/formulations for children. |
| Year(s) Of Engagement Activity | 2018,2021 |
| Description | Membership of the WHO Paediatric Antiretroviral Working Group (PAWG) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Providing expert opinion for the WHO Paediatric Antiretroviral Working Group (PAWG), related to prevention, treatment and development of new drugs for children. |
| Year(s) Of Engagement Activity | 2016,2017,2018,2019,2020,2021 |
| Description | Membership of the WHO Paediatric Working Group on Viral Hepatitis (PWGH) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Providing expert opinion for the WHO Paediatric Working Group on Viral Hepatitis (PWGH), related to prevention, treatment and development of new drugs for children. |
| Year(s) Of Engagement Activity | 2020,2021 |
| Description | Oral presentation at 2020 Union Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Shorter treatment for minimal tuberculosis in children: main findings from the SHINE trial- Oral presentation at 2020 Union Conference (ref: LB-2056-24) |
| Year(s) Of Engagement Activity | 2020 |
| Description | Oral presentation at 2020 Union Conference (ref: OA-34-711-24) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation at 2020 Union Conference (ref: OA-34-711-24): 'Diagnostic utility of microbiological and histopathological testing in the diagnosis of Paediatric TB lymphadenitis in Indian children screened for the SHINE trial.' |
| Year(s) Of Engagement Activity | 2020 |
| Description | Penta English and Russian courses in Paediatric HIV, hepatitis and congenital infections - preparation and update of online modules and tutorial support |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Incorporating latest evidence from the research studies, including those conducted by MRC CTU at UCL, in the interactive modules on Epidemiology and natural Infection; HIV: diagnosis, staging and role of co-infections and malignancy; Co-infections: Hepatitis and TB. Tutorial support during annually conducted courses. Lectures at the residential and virtual (from 2020) courses. |
| Year(s) Of Engagement Activity | 2013,2014,2015,2016,2017,2018,2019,2020,2021 |
| Description | Poster Presentation at International Workshop on HIV Pediatrics 2020. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation titled: 'Cascade of care in children and adolescents with HIV in Russian Federation' Anna Turkova, Edith Milanzi, Siobhan Crichton, Charlotte Jackson, Ali Judd, Intira J Collins, on behalf of the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) International Workshop on HIV Pediatrics 2020. 16-17 November 2020. Poster#68 |
| Year(s) Of Engagement Activity | 2020 |
| Description | Poster presentation at 2020 Union Conference (ref: EP02-112-21) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at 2020 Union Conference (ref: EP02-112-21): 'A method for baseline adjudication of tuberculosis diagnosis in children in a therapeutic clinical trial: experience from SHINE.' |
| Year(s) Of Engagement Activity | 2020 |
| Description | Poster presentation at 2020 Union Conference (ref: EP02-114-21) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at 2020 Union Conference (ref: EP02-114-21): 'Utility of colour vision testing for screening for ethambutol-associated ocular toxicity in children treated for TB in the SHINE trial.' |
| Year(s) Of Engagement Activity | 2020 |
| Description | Poster presentation at 2020 Union Conference (ref: EP15-241-22) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at 2020 Union Conference (ref: EP15-241-22): 'Caregivers' beliefs in anti-tuberculosis medicines in the African/Indian SHINE trial.' |
| Year(s) Of Engagement Activity | 2020 |
| Description | Poster presentation at 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2020. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation titled: 'Characteristics and cascade of HIV care in children with perinatally acquired HIV in three Russian clinics. Edith Milanzi, Siobhan Crichton,Charlotte Jackson, Ali Judd3, Intira J Collins, Anna Turkova on behalf of the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) et al. 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), 26-29 October 2020. Poster#740 |
| Year(s) Of Engagement Activity | 2020 |
| Description | Presentation of BREATHER (PENTA 16) qualitative results |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team. "But it's my story": exploring the experience and effect of telling children how they have acquired HIV; 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://penta-id.org |
| Description | Presentation of BREATHER and ARROW qualitative work |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams 'I am scared of getting caught up in my lie': challenges to self-reported adherence for young people living with HIV; accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435) |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://penta-id.org |
| Description | Presentation of further results of BREATHER (PENTA 16) qualitative work |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team. Young people, clinical trials and 'the HIV experience': What can similarities across time and place tell us about growing up with HIV? 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://penta-id.org |
| Description | Presentation of qualitative work in BREATHER (PENTA 16 ) in the UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Bernays S, Seeley J, Paparini S, Rhodes T and the BREATHER trial teams 'I was like, oh my God, what happens if it doesn't work'?: young people living with HIV, clinical trial participation, and the truth economy accepted for presentation at BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148). |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://penta-id.org |
| Description | SHINE trial results Presentation at the annual WHO Child and Adolescent TB working Group Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | SHINE trial results were presented at the WHO Child and Adolescent TB working Group Meeting (October 2020). In May 2021 the SHINE trial results will be presented at WHO guideline committee. |
| Year(s) Of Engagement Activity | 2020 |
| Description | SMILE (PENTA 17) Final Results Presentation with the WHO |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | A post results trial meeting with WHO (17 Feb 2021) to discuss trial results and consider where they could fit into guidelines. |
| Year(s) Of Engagement Activity | 2021 |
| Description | SMILE results presented as a poster/oral presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | The SMILE results were presented as a poster at IAS Conference on HIV Science in July 2021, and as an oral presentation at the HIV paediatric workshop (just before IAS). Title was 'ONCE-DAILY INTEGRASE INHIBITOR (INSTI) WITH BOOSTED DARUNAVIR IS NON-INFERIOR TO STANDARD OF CARE IN VIROLOGICALLY SUPPRESSED CHILDREN - WEEK 48 RESULTS OF THE SMILE PENTA-17 TRIAL' |
| Year(s) Of Engagement Activity | 2021 |
| Description | Stand at International AIDS Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We had a stand at the International AIDS Conference in Durban, distributing outputs from our HIV studies including policy briefs, graphic novels, films and video case studies and other training materials. |
| Year(s) Of Engagement Activity | 2016 |
| Description | TRACT 20mls vs 30mls animated abstract |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This animated abstract summarises the results of the TRACT trial in relation to the volume of blood children with severe anaemia require. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://vimeo.com/344562147 |
| Description | TRACT briefing paper on 20mls vs 30mls transfusions |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | This briefing paper describes the results of the TRACT trial in relation to the volume required for blood transfusions for children with severe anaemia, and examines the implications for policy and practice. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.ctu.mrc.ac.uk/media/1709/tract-20vs30mls-briefing-final-020819.pdf |
| Description | TRACT film |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This film explores the results and implications of the TRACT trial. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://vimeo.com/350115186 |
| Description | TRACT immediate vs no immediate transfusion animated abstract |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This short animation summarises the results of the TRACT trial in relation to whether children with uncomplicated severe anaemia require an immediate transfusion. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://vimeo.com/344562242 |
| Description | TRACT immediate vs no immediate transfusion briefing paper |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | This briefing paper describes the results of the TRACT trial in relation to immediate vs no immediate transfusion for children with uncomplicated severe anaemia, and examines the implications for policy and practice. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.ctu.mrc.ac.uk/media/1710/tract-immediate-vs-no-immediate-transfusion-briefing-final-0208... |
| Description | TRACT immediate vs no immediate transfusion infographic |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This infographic summarises the results of the TRACT trial in terms of immediate vs no immediate transfusion for children with uncomplicated severe anaemia. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.ctu.mrc.ac.uk/media/1707/full-infographic-immediate-vs-no-immediate-transfusion-020819.p... |
| Description | TRACT international stakeholders meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We held a stakeholder meeting for paediatricians and blood transfusion services from across sub-Saharan Africa, to explore the implications of the TRACT trial for policy and practice. At the meeting we developed an algorithm for managing children with suspected severe anaemia. |
| Year(s) Of Engagement Activity | 2020 |
| Description | TRACT transfusion volume infographic |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This infographic summarises the results of the TRACT trial in relation to the volume of blood required for transfusion for children with severe anaemia. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.ctu.mrc.ac.uk/media/1708/full-infographic-transfusion-volume-020819.png |
| Description | The Lancet HIV Podcast interview regarding paediatric HIV treatment and the pharmacokinetic substudy of the ODYSSEY trial of dolutegravir for children with HIV. |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Dr Anna Turkova and Prof Di Gibb joined the The Lancet HIV Editor-in-Chief Peter Hayward to discuss paediatric HIV treatment and the pharmacokinetic substudy of the ODYSSEY trial of dolutegravir for children with HIV. |
| Year(s) Of Engagement Activity | 2020 |
| Description | WHO Paediatric Antiretroviral Drug Optimisation (PADO) - 4th meeting. Invited talk: Treatment Simplification Strategies |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | PADO group is WHO-led international group of different stakeholders aimed to define antiretroviral drugs for medium and long-term development for children living with HIV. PADO group meetings are held every 1-2 years. The talk summarised the evidence on the new simplification regimens for treatment of HIV. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/pado4.pdf?sfvrsn=26d... |
| Description | WHO Press release/newsflash on SHINE results (Oct 2020) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | WHO Press release/newsflash on SHINE results (Oct 2020) |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.who.int/news/item/26-10-2020-shine-trial-on-shorter-treatment-for-children-with-minimal-... |
| Description | Webinar Series: Non-tuberculous bacterial infections in advanced HIV disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented 'Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy' at the CDC/CHAI/Unitaid Advanced HIV Disease Global ECHO Webinar Series session 'Non-tuberculous bacterial infections in advanced HIV disease.' |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://hsc.unm.edu/echo/institute-programs/covid-19-response/international-covid19/cdc-hiv/ |
| Description | Youth Trial Board meeting with MRC CTU |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | We held a meeting with the UK Youth Trial Board to share our research and get their feedback. |
| Year(s) Of Engagement Activity | 2017 |